Log In
Print
BCIQ
Print
Print this Print this
 

IMGN289

  Manage Alerts
Collapse Summary General Information
Company ImmunoGen Inc.
DescriptionHumanized mAb against EGFR linked to Immunogen's DM1 cytotoxic agent
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat EGFR-positive solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today